DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
UCENPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
UCENPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIBEVITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LIBEVITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ASKP1240
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ASKP1240
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRILIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 negative modulator
PRILIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENOTICUMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ENOTICUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLINTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
OLINTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-210
2
Antibody
Investigational
Unknown
Unknown
Unknown
High affinity immunoglobulin gamma Fc receptor I cross-linking agent
MDX-210
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VEPALIMOMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Amine oxidase, copper containing inhibitor
VEPALIMOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0M19J59UH4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY2541546
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LY2541546
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAT-203
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
CAT-203
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
H11 SCFV
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
H11 SCFV
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LULIZUMAB PEGOL
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell-specific surface glycoprotein CD28 antagonist
LULIZUMAB PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
LCT264LTYE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VONLEROLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Urinary Bladder Neoplasms
Unknown
VONLEROLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
C78148TF1D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEMPIKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BEMPIKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ITEPEKIMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
Interleukin-33 inhibitor
ITEPEKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WV9KZ9PS1A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLETIKUMAB
2
Antibody
Investigational
Unknown
Unknown
Psoriasis; Arthritis, Rheumatoid; Inflammation
Interleukin-20 inhibitor
FLETIKUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
82WG3POL9W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRX-1
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 inhibitor
TRX-1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FELMETATUG VEDOTIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
FELMETATUG VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JTX-2011
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
JTX-2011
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PAGIBAXIMAB
2
Antibody
Investigational
Unknown
Unknown
Sepsis
Lipoteichoic acid inhibitor
PAGIBAXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CALOTATUG GINISTINAG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CALOTATUG GINISTINAG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RAGISTOMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
RAGISTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SEMORINEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Microtubule-associated protein tau inhibitor
SEMORINEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
O8DG8VI95O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OMECTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
OMECTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UMIKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
UMIKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ITANISTOMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ITANISTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMGATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Head and Neck Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
IMGATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
V77J4WJF9Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MM-302
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MM-302
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
J591 177LU
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
J591 177LU
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OZEKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
OZEKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FPA144
2
Antibody
Investigational
Unknown
Unknown
Stomach Neoplasms
Fibroblast growth factor receptor 2 inhibitor
FPA144
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TALACOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interleukin-3 receptor subunit alpha binding agent
TALACOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
X8JR0I7JE1
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZANOLIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lymphoma; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome
T-cell surface antigen CD4 other
ZANOLIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
HG3L8885M0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OZUREPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
OZUREPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FIZTASOVIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
FIZTASOVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
12
13
14
15
16
17
18
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA